Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation

Abstract

Radiopharmaceuticals are reshaping the landscape of cancer therapy, offering a unique theranostic advantage that is becoming increasingly central to precision medicine. By labeling the same molecular scaffold with different radionuclides, these agents enable seamless integration of diagnostic imaging and targeted therapy. Clinical breakthroughs with somatostatin receptor subtype 2 (SSTR2)-and prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals have significantly enhanced both tumor visualization and therapeutic efficacy, establishing new benchmarks in oncology. Ongoing research is exploring novel molecular targets such as cholecystokinin-2 receptor (CCK2R), fibroblast activation protein (FAP), and C-X-C chemokine receptor type 4 (CXCR4). In parallel, there is growing interest in utilizing alternative radionuclides, including alpha-particle emitters and Auger electron emitters, beyond the commonly used beta-emitters, to improve therapeutic outcomes. Simultaneously, advances in ligand and linker design are being leveraged to optimize in vivo pharmacokinetics and tissue distribution. Among the emerging targets, CCK2R has attracted notable attention due to its overexpression in multiple malignancies. Research efforts have focused on improving ligand stability, receptor-binding affinity, and tumor retention, while also exploring strategies to enhance CCK2R expression on cancer cells. This review offers a comprehensive overview of the current landscape in cancer radiotheranostics, exploring the role of CCK2R in cancer biology and summarizing the latest advancements in the development of CCK2R-targeted radiopharmaceuticals. Using these advancements as a case study, we systematically examine key aspects of next-generation radiopharmaceutical design, from target selection and ligand engineering to pharmacokinetic optimization and clinical translation, providing a multidimensional framework for future innovation in cancer radiotheranostics.

Keywords

cancer theranostics / CCK2R / molecular targets / radiopharmaceuticals / radiotheranostics

References

[1] Lapi SE, Scott PJH, Scott AM, Windhorst AD, Zeglis BM, Abdel-Wahab M, et al. Recent advances and impending challenges for the radiopharmaceutical sciences in oncology. Lancet Oncol. 2024;25(6):e236–e49.

[2] Moreno-Alcántar G, Drexler M, Casini A. Assembling a new generation of radiopharmaceuticals with supramolecular theranostics. Nat Rev Chem. 2024:1–22.

[3] Bodei L, Herrmann K, Schöder H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19(8):534–50.

[4] Abdel-Wahab M, Giammarile F, Carrara M, Paez D, Hricak H, Ayati N, et al. Radiotherapy and theranostics: A lancet oncology commission. Lancet Oncol. 2024;25(11):e545–e80.

[5] Caplin M. The Recent European Approval of Lutetium (177Lu) Oxodotreotide Increases Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. Int J Endocr Oncol. 2018;5(2):IJE09.

[6] Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, et al. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2023;29(9):1651–7.

[7] Hennrich U, Eder M. [(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer. Pharmaceuticals. 2021;14(8):713.

[8] Sundlöv A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, et al. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based (177)Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging. 2022;49(11):3830–40.

[9] Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016;70(6):926–37.

[10] Huang S, Ong S, McKenzie D, Mirabelli A, Chen DC, Chengodu T, et al. Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer—a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2024;27(4):654–64.

[11] Turner JH. Recent advances in theranostics and challenges for the future. Br J Radiol. 2018;91(1091):20170893.

[12] Koller L, Joksch M, Schwarzenböck S, Kurth J, Heuschkel M, Holzleitner N, et al. Preclinical comparison of the 64Cu-and 68Ga-labeled GRPR-targeted compounds RM2 and AMTG, as well as first-in-humans [68Ga] Ga-AMTG PET/CT. J Nucl Med. 2023;64(10):1654–9.

[13] Holzleitner N, Cwojdzinski T, Beck R, Urtz-Urban N, Hillhouse CC, Grundler PV, et al. Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with 161Tb and 177Lu: A Comparative Study. J Nucl Med. 2024;65(3):481–4.

[14] Dreher N, Hahner S, Fuß CT, Schlötelburg W, Hartrampf PE, Serfling SE, et al. CXCR4-directed PET/CT with [68 Ga] Ga-pentixafor in solid tumors—A comprehensive analysis of imaging findings and comparison with histopathology. Eur J Nucl Med Mol Imaging. 2024;51(5):1383–94.

[15] Enke JS, Reitsam NG, Grosser B, Kircher M, Dierks A, Bundschuh RA, et al. CXC motif chemokine receptor 4–directed scintigraphy of multiple myeloma using [99mTc] Tc-PentixaTec. J Nucl Med. 2024;65(1):163–4.

[16] Baum RP, Singh A, Schuchardt C, Kulkarni HR, Klette I, Wiessalla S, et al. 177Lu-3BP-227 for neurotensin receptor 1–targeted therapy of metastatic pancreatic adenocarcinoma: first clinical results. J Nucl Med. 2018;59(5):809–14.

[17] von Guggenberg E, Kolenc P, Rottenburger C, Mikołajczak R, Hubalewska-Dydejczyk A. Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals. Cancers. 2021;13(22):5776.

[18] Al-Ibraheem A, Badarneh M, Abdlkadir AS, Al-Qasem S, Ruzzeh S, Giammarile F. Investigating the diffuse pancreatic expression of [68Ga] Ga-DOTA-FAPI: location, timing, and molecular imaging approaches. Clin & Transl Imag. 2024;12(5):451–5.

[19] Zhang Q, Hu Z, Zhao H, Du F, Lv C, Peng T, et al. Design, Synthesis, and Biological Evaluation of a Novel [18F] AlF-H3RESCA-FAPI Radiotracer Targeting Fibroblast Activation Protein. Pharmaceuticals. 2025;18(2):277.

[20] Zhang Z, Guo S, Su W, Pan G, Cao K, Jiang H, et al. Preoperative assessment of pancreatic cancer with [68Ga] Ga-DOTA-FAPI-04 PET/MR versus [18F]-FDG PET/CT plus contrast-enhanced CT: a prospective preliminary study. Eur J Nucl Med Mol Imaging. 2025;52(3):1017–27.

[21] Wang X, Dai D, Shen J, Zhang S, Ohkubo T, Xie L, et al. A Cyclic Peptide-Based Radiotheranostic Agent for Urokinase-Type Plasminogen Activator in Tumors. Chem. 2025;31(28):e202500479.

[22] Sun L, Sun Y, Zuo K, Fan L, Wang X, Zhang J, et al. Pilot Study of Nectin-4-Targeted PET Imaging Agent (68)Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human. J Nucl Med. 2025;66(3):473–9.

[23] Ludwig F-A, Laurini E, Schmidt J, Pricl S, Deuther-Conrad W, Wünsch B. [18F] Fluspidine—A PET Tracer for Imaging of σ1 Receptors in the Central Nervous System. Pharmaceuticals. 2024;17(2):166.

[24] Sui H, Guo F, Liu H, Wang R, Li L, Wang J, et al. Safety, pharmacokinetics, and dosimetry of 177Lu-AB-3PRGD2 in patients with advanced integrin αvβ3-positive tumors: A first-in-human study. Acta Pharmaceutica Sinica B. 2024.

[25] Chandekar KR, Prashanth A, Vinjamuri S, Kumar R. FAPI PET/CT Imaging-An Updated Review. Diagnostics (Basel). 2023;13(12):2018.

[26] Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation Dosimetry and Biodistribution of (68)Ga-FAPI-46 PET Imaging in Cancer Patients. J Nucl Med. 2020;61(8):1171–7.

[27] Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 2022;49(11):3651–67.

[28] Wen X, Xu P, Shi M, Liu J, Zeng X, Zhang Y, et al. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics. 2022;12(1):422–33.

[29] Fu H, Huang J, Zhao L, Chen Y, Xu W, Cai J, et al. 177Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers: A Single-Center, Single-Arm, Phase II Study. Clin Cancer Res. 2025;31(8):1415–26.

[30] Dalm SU, Bakker IL, de Blois E, Doeswijk GN, Konijnenberg MW, Orlandi F, et al. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2017;58(2):293–9.

[31] Watts A, Singh B, Singh H, Bal A, Kaur H, Dhanota N, et al. [(68)Ga]Ga-Pentixafor PET/CT imaging for in vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: correlation with quantitative receptors' density by immunochemistry techniques. Eur J Nucl Med Mol Imaging. 2023;50(4):1216–27.

[32] Jacobs SM, Wesseling P, de Keizer B, Tolboom N, Ververs FFT, Krijger GC, et al. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [(68)Ga]Ga-Pentixafor /[(177)Lu]Lu-Pentixather. Eur J Nucl Med Mol Imaging. 2022;49(2):481–91.

[33] Schulz J, Rohracker M, Stiebler M, Goldschmidt J, Stöber F, Noriega M, et al. Proof of Therapeutic Efficacy of a (177)Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model. J Nucl Med. 2017;58(6):936–41.

[34] Klingler M, Summer D, Rangger C, Haubner R, Foster J, Sosabowski J, et al. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use. J Nucl Med. 2019;60(7):1010–6.

[35] Di Santo G, Santo G, Martinovic V, Wolf D, Pircher A, Sviridenko A, et al. Cholecystokinin-2 receptor targeting by [(68)Ga]Ga-DOTA-MGS5 PET/CT in a patient with extensive disease small cell lung cancer. Eur J Nucl Med Mol Imaging. 2024;51(9):2848–9.

[36] Günther T, Holzleitner N, Viering O, Beck R, Wienand G, Dierks A, et al. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [(68)Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer. J Nucl Med. 2024;65(1):33–9.

[37] Zavvar TS, Hörmann AA, Konijnenberg M, Kraihammer M, Mair C, Kronthaler A, et al. Radiopharmaceutical formulation and preliminary clinical dosimetry of [(177)Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2025;52(4):1321–31.

[38] Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33–48.

[39] Liu X, Deng J, Yuan Y, Chen W, Sun W, Wang Y, et al. Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer. Pharmacol Ther. 2022;239:108296.

[40] Wang C, Wang Y, Chen J, Wang Y, Pang C, Liang C, et al. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer. BMC Gastroenterol. 2023;23(1):283.

[41] Rudin CM, Reck M, Johnson ML, Blackhall F, Hann CL, Yang JC, et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol. 2023;16(1):66.

[42] An S, Zhang D, Zhang Y, Wang C, Shi L, Wei W, et al. GPC3-targeted immunoPET imaging of hepatocellular carcinomas. Eur J Nucl Med Mol Imaging. 2022;49(8):2682–92.

[43] Gandy N, Arshad MA, Park WE, Rockall AG, Barwick TD. FDG-PET Imaging in Cervical Cancer. Semin Nucl Med. 2019;49(6):461–70.

[44] Zhang X, Son MH, Ha LN, Lan X. PSMA-based (18)F-DCFPyL PET: a better choice than multiparametric MRI for prostate cancer diagnosis? Am J Nucl Med Mol Imaging. 2022;12(6):195–200.

[45] Hennrich U, Eder M. [(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer. Pharmaceuticals (Basel). 2021;14(8):713.

[46] Jones S, Hendel RC. Technetium-99m tetrofosmin: a new myocardial perfusion agent. J Nucl Med Technol. 1993;21(4):191–5.

[47] Sarwar A, Malik MS, Vo NH, Tsai LL, Tahir MM, Curry MP, et al. Efficacy and Safety of Radiation Segmentectomy with (90)Y Resin Microspheres for Hepatocellular Carcinoma. Radiology. 2024;311(2):e231386.

[48] Hennrich U, Eder M. [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals (Basel). 2022;15(10):1292.

[49] Warfvinge CF, Gustafsson J, Roth D, Tennvall J, Svensson J, Bernhardt P, et al. Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [(177)Lu]Lu-DOTATATE. J Nucl Med. 2024;65(7):1070–5.

[50] Watabe T, Liu Y, Kaneda-Nakashima K, Sato T, Shirakami Y, Ooe K, et al. Comparison of the Therapeutic Effects of [(211)At]NaAt and [(131)I]NaI in an NIS-Expressing Thyroid Cancer Mouse Model. Int J Mol Sci. 2022;23(16):9434.

[51] Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, et al. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41(11):2106–19.

[52] Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2016;57(12):1941–4.

[53] Leung CN, Canter BS, Rajon D, Bäck TA, Fritton JC, Azzam EI, et al. Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with (223)Ra: The Role of Bystander Effects and Their Potential for Therapy. J Nucl Med. 2020;61(1):89–95.

[54] Canter BS, Leung CN, Fritton JC, Bäck T, Rajon D, Azzam EI, et al. Radium-223-Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow. Mol Cancer Res. 2021;19(10):1739–50.

[55] Yang M, Wang L, Qin S, Dai X, Li J, An L, et al. Role of damaged mitochondrial transfer in alpha-particle generator (212)Pb radiation-induced bystander effect. Theranostics. 2024;14(17):6768–82.

[56] Eapen RS, Williams SG, Macdonald S, Keam SP, Lawrentschuk N, Au L, et al. Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer. Nat Rev Urol. 2024;21(11):676–86.

[57] Lunj S, Smith TAD, Reeves KJ, Currell F, Honeychurch J, Hoskin P, et al. Immune effects of α and β radionuclides in metastatic prostate cancer. Nat Rev Urol. 2024;21(11):651–61.

[58] Ballal S, Yadav MP, Satapathy S, Raju S, Tripathi M, Damle NA, et al. Long-term survival outcomes of salvage [(225)Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study. Eur J Nucl Med Mol Imaging. 2023;50(12):3777–89.

[59] Wen X, Zhao T, Yang H, Shi M, Wee XJ, Fu J, et al. Development of [(225)Ac]Ac‑LNC1011 for targeted alpha-radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52(8):2841–55.

[60] Saidi A, Stallons TA, Wong AG, Torgue JJ. Preclinical Investigation of [(212)Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model. J Nucl Med. 2024;65(11):1769–75.

[61] Holzleitner N, Vilangattil M, Swaidan A, Garcia-Prada CD, Taddio MF, Jeanjean P, et al. Preclinical evaluation of 225Ac-labeled minigastrin analog DOTA-CCK-66 for Targeted Alpha Therapy. Eur J Nucl Med Mol Imaging. 2024;52(2):458–68.

[62] Müller D, Herrmann H, Schultz MK, Solbach C, Ettrich T, Prasad V. 203 Pb-VMT-α-NET Scintigraphy of a Patient With Neuroendocrine Tumor. Clin Nucl Med. 2023;48(1):54–5.

[63] Nelson BJB, Andersson JD, Wuest F. Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications. Pharmaceutics. 2021;13(1):49.

[64] Spoormans K, Struelens L, Vermeulen K, De Saint-Hubert M, Koole M, Crabbé M. The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for (161)Tb Compared with (177)Lu with a Higher Dose Response for [(161)Tb]Tb-DOTA-LM3 Than for [(161)Tb]Tb-DOTATATE. J Nucl Med. 2024;65(10):1619–25.

[65] Bolcaen J, Gizawy MA, Terry SYA, Paulo A, Cornelissen B, Korde A, et al. Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy. J Nucl Med. 2023;64(9):1344–51.

[66] Osytek KM, Blower PJ, Costa IM, Smith GE, Abbate V, Terry SYA. In vitro proof of concept studies of radiotoxicity from Auger electron-emitter thallium-201. EJNMMI Res. 2021;11(1):63.

[67] Reubi JC. Targeting CCK receptors in human cancers. Curr Top Med Chem. 2007;7(12):1239–42.

[68] Béhé M, Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers. 2002;66(6):399–418.

[69] Zeng Q, Ou L, Wang W, Guo D-Y. Gastrin, cholecystokinin, signaling, and biological activities in cellular processes. Front Endocrinol. 2020;11:112.

[70] Wank SA. Cholecystokinin receptors. Am J Physiology-Gastrointestinal and Liver Physiol. 1995;269(5):G628–G46.

[71] Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer. 1996;67(5):644–7.

[72] Camby I, Salmon I, Danguy A, Pasteels J-L, Brotchi J, Martinez J, et al. Influence of gastrin on human astrocytic tumor cell proliferation. J Natl Cancer Inst. 1996;88(9):594–600.

[73] Matsumori Y, Katakami N, Ito M, Taniguchi T, Iwata N, Takaishi T, et al. Cholecystokinin-B/gastrin receptor: a novel molecular probe for human small cell lung cancer. Cancer Res. 1995;55(2):276–9.

[74] Upp JR, Singh P, Townsend CM, Thompson JC. Clinical significance of gastrin receptors in human colon cancers. Cancer Res. 1989;49(2):488–92.

[75] Borgna F, Haller S, Rodriguez JMM, Ginj M, Grundler PV, Zeevaart JR, et al. Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2022;49(4):1113–26.

[76] Behr TM, Jenner N, Radetzky S, Béhe M, Gratz S, Yücekent S, et al. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med. 1998;25(4):424–30.

[77] Behr TM, Béhé M, Angerstein C, Gratz S, Mach R, Hagemann L, et al. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res. 1999;5(10):3124s–38s.

[78] Copps J, Murphy RF, Lovas S. The production and role of gastrin-17 and gastrin-17-gly in gastrointestinal cancers. Protein Pept Lett. 2009;16(12):1504–18.

[79] Klingler M, Hörmann AA, von Guggenberg E. Cholecystokinin-2 receptor targeting with radiolabeled peptides: current status and future directions. Curr Med Chem. 2020;27(41):7112–32.

[80] Kolenc-Peitl P, Mansi R, Tamma M, Gmeiner-Stopar T, Sollner-Dolenc M, Waser B, et al. Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. J Med Chem. 2011;54(8):2602–9.

[81] Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, et al. Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study. J Nucl Med. 2020;61(4):520–6.

[82] Erba PA, Maecke H, Mikolajczak R, Decristoforo C, Zaletel K, Maina-Nock T, et al. A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: A multicenter phase I GRAN-T-MTC study. Polish archives of internal medicine. 2018;128(12):791.

[83] Fröberg AC, de Jong M, Nock BA, Breeman WA, Erion JL, Maina T, et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009;36(8):1265–72.

[84] Béhé M, Kluge G, Becker W, Gotthardt M, Behr TM. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med. 2005;46(6):1012–5.

[85] Kaloudi A, Nock BA, Lymperis E, Krenning EP, de Jong M, Maina T. Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon. Cancer Biother Radiopharm. 2016;31(1):20–8.

[86] Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, et al. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog 177Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution? J Nucl Med. 2019;60(3):393–9.

[87] Klingler M, Hörmann AA, Rangger C, Desrues L, Castel Hln, Gandolfo P, et al. Stabilization strategies for linear minigastrin analogues: Further improvements via the inclusion of proline into the peptide sequence. J Med Chem. 2020;63(23):14668–79.

[88] Grob NM, Häussinger D, Deupi X, Schibli R, Behe M, Mindt TL. Triazolo-Peptidomimetics: Novel Radiolabeled Minigastrin Analogs for Improved Tumor Targeting. J Med Chem. 2020;63(9):4484–95.

[89] Silvente-Poirot S, Escrieut C, Wank SA. Role of the extracellular domains of the cholecystokinin receptor in agonist binding. Mol Pharmacol. 1998;54(2):364–71.

[90] Holzleitner N, Günther T, Daoud-Gadieh A, Lapa C, Wester H-J. Investigation of the structure-activity relationship at the N-terminal part of minigastrin analogs. EJNMMI Res. 2023;13(1):65.

[91] Rahimi MN, Corlett A, Zuylekom JV, Sani MA, Blyth B, Thompson P, et al. Precision peptide theranostics: developing N- to C-terminus optimized theranostics targeting cholecystokinin-2 receptor. Theranostics. 2024;14(5):1815.

[92] Good S, Walter MA, Waser B, Wang X, Müller-Brand J, Béhé MP, et al. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging. 2008;35:1868–77.

[93] Klingler M, Summer D, Rangger C, Haubner R, Foster J, Sosabowski J, et al. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use. J Nucl Med. 2019;60(7):1010–6.

[94] Hörmann AA, Klingler M, Rangger C, Mair C, Decristoforo C, Uprimny C, et al. Radiopharmaceutical Formulation and Preclinical Testing of 68Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial. Pharmaceuticals. 2021;14(6):575.

[95] Zavvar TS, Hörmann AA, Klingler M, Summer D, Rangger C, Desrues L, et al. Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs. Pharmaceuticals. 2023;16(2):278.

[96] Hörmann AA, Klingler M, Rezaeianpour M, Hörmann N, Gust R, Shahhosseini S, et al. Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177. Molecules. 2020;25(19):4585.

[97] Hörmann AA, Plhak E, Klingler M, Rangger C, Pfister J, Schwach G, et al. Automated Synthesis of 68Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting. Molecules. 2022;27(6):2034.

[98] Günther T, Holzleitner N, Viering O, Beck R, Wienand G, Dierks A, et al. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer. J Nucl Med. 2024;65(1):33–9.

[99] Grob NM, Schibli R, Béhé M, Mindt TL. Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin 177Lu-PP-F11N. Cancers. 2021;13(11):2629.

[100] Corlett A, Sani M-A, Van Zuylekom J, Ang C-S, von Guggenberg E, Cullinane C, et al. A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive Cancer. J Med Chem. 2021;64(8):4841–56.

[101] Khan N-U-H, Corlett A, Hutton CA, Haskali MB. Investigation of Fluorine-18 Labelled Peptides for Binding to Cholecystokinin-2 Receptors with High Affinity. Int J Pept Res Ther. 2022;28:1–11.

[102] Günther T, Holzleitner N, Di Carlo D, Urtz-Urban N, Lapa C, Wester H-J. Development of the First 18F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety. Pharmaceutics. 2023;15(3):826.

[103] Holzleitner N, Fischer S, Maniyankerikalam I, Beck R, Lapa C, Wester H-J, et al. Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs. EJNMMI Res. 2024;14(1):23.

[104] Ubl P, Gincu T, Keilani M, Ponhold L, Crevenna R, Niederle B, et al. Comparison of side effects of pentagastrin test and calcium stimulation test in patients with increased basal calcitonin concentration: the gender-specific differences. Endocrine. 2014;46:549–53.

[105] Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands-the next generation for clinical practice. Am J Nucl Med & Mol Imag. 2018;8(5):311.

[106] Bison SM, Konijnenberg MW, Melis M, Pool SE, Bernsen MR, Teunissen JJ, et al. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clin & Transl Imag. 2014;2:55–66.

[107] Fani M, Nicolas GP, Wild D. Somatostatin receptor antagonists for imaging and therapy. J Nucl Med. 2017;58(Supplement 2):61S–6S.

[108] Boyce M, Lloyd KA, Pritchard DM. Potential clinical indications for a CCK2 receptor antagonist. Curr Opin Pharmacol. 2016;31:68–75.

[109] Chau I, Cunningham D, Russell C, Norman A, Kurzawinski T, Harper P, et al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006;94(8):1107–15.

[110] Morton MF, Barrett TD, Freedman J, Li L, Rizzolio MC, Prendergast CE, et al. JNJ-26070109 [(R) 4-bromo-N-[1-(2, 4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. J Pharmacol Exp Ther. 2011;338(1):328–36.

[111] Fossmark R, Sørdal Ø, Jianu C, Qvigstad G, Nordrum I, Boyce M, et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther. 2012;36(11-12):1067–75.

[112] Lavigne G, Millington W, Mueller G. The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260, enhance morphine antinociception only in non-acclimated rats exposed to a novel environment. Neuropeptides. 1992;21(2):119–29.

[113] Kawasaki D, Emori Y, Eta R, Iino Y, Hamano H, Yoshinaga K, et al. Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro. Cancer Chemother Pharmacol. 2008;61:883–92.

[114] Ueno M, Li CP, Ikeda M, Ishii H, Mizuno N, Yamaguchi T, et al. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo. Cancer Chemother Pharmacol. 2017;80:307–15.

[115] Wayua C, Low PS. Evaluation of a Nonpeptidic Ligand for Imaging of Cholecystokinin 2 Receptor–Expressing Cancers. J Nucl Med. 2015;56(1):113–9.

[116] Wayua C, Low PS. Evaluation of a cholecystokinin 2 receptor-targeted near-infrared dye for fluorescence-guided surgery of cancer. Mol Pharmaceutics. 2014;11(2):468–76.

[117] Nock BA, Kanellopoulos P, Chepurny OG, Rouchota M, Loudos G, Holz GG, et al. Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK2R Cancer Theranostic Agents: A Preclinical Study. Pharmaceutics. 2022;14(3):666.

[118] Vettorato E, Verona M, Bellio G, Croci S, Filadi R, Bisio A, et al. Development and Validation of Novel Z-360-Based Macromolecules for the Active Targeting of CCK2-R. Mol Pharmaceutics. 2024;21(8):3848–65.

[119] Pavone AM, Benfante V, Giaccone P, Stefano A, Torrisi F, Russo V, et al. Biodistribution Assessment of a Novel 68Ga-Labeled Radiopharmaceutical in a Cancer Overexpressing CCK2R Mouse Model: Conventional and Radiomics Methods for Analysis. Life. 2024;14(3):409.

[120] Grzmil M, Qin Y, Schleuniger C, Frank S, Imobersteg S, Blanc A, et al. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [177Lu]Lu-PP-F11N. Theranostics. 2020;10(24):10861–73.

[121] Grzmil M, Wiesmann F, Schibli R, Behe M. Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer. Cancers. 2022;15(1):17.

[122] Lezaic L, Erba PA, Decristoforo C, Zaletel K, Mikolajczak R, Maecke H, et al. [111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial. Eur J Nucl Med Mol Imaging. 2022;50(3):892.

[123] Rottenburger C, Hentschel M, Fürstner M, McDougall L, Kottoros D, Kaul F, et al. In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study. EJNMMI Res. 2024;14(1):37.

[124] Guggenberg Ev, Uprimny C, Klinger M, Warwitz B, Sviridenko A, Bayerschmidt S, et al. Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer. J Nucl Med. 2023;64(6):859–62.

[125] Viering O, Holzleitner N, Claus R, Amerein A, Dreher N, Enke JS, et al. CCK2 Receptor Ligand [68Ga] Ga-DOTA-CCK-66 PET/CT Outperforms [68Ga] Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer. J Nucl Med. 2025;66(4):662.

[126] Zavvar TS, Hörmann AA, Konijnenberg M, Kraihammer M, Mair C, Kronthaler A, et al. Radiopharmaceutical formulation and preliminary clinical dosimetry of [177Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2024:1–11.

[127] Viering O, Rinscheid A, Holzleitner N, Dierks A, Kircher M, Wienand G, et al. Biodistribution and Radiation Dosimetry for 68Ga-DOTA-CCK-66, a Novel CCK2R-Targeting Compound for Imaging of Medullary Thyroid Cancer. Clin Nucl Med. 2024;49(12):1091.

[128] Funeh CN, Bridoux J, Ertveldt T, De Groof TW, Chigoho DM, Asiabi P, et al. Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy. Pharmaceutics. 2023;15(5):1378.

[129] Brandt F, Ullrich M, Wodtke J, Kopka K, Bachmann M, Löser R, et al. Enzymological characterization of 64Cu-labeled neprilysin substrates and their application for modulating the renal clearance of targeted radiopharmaceuticals. J Med Chem. 2023;66(1):516–37.

[130] Uehara T, Yokoyama M, Suzuki H, Hanaoka H, Arano Y. A gallium-67/68–labeled antibody fragment for immuno-SPECT/PET shows low renal radioactivity without loss of tumor uptake. Clin Cancer Res. 2018;24(14):3309–16.

[131] Suzuki H, Kise S, Kaizuka Y, Watanabe R, Sugawa T, Furukawa T, et al. Copper-64-labeled antibody fragments for immuno-PET/radioimmunotherapy with low renal radioactivity levels and amplified tumor-kidney ratios. ACS omega. 2021;6(33):21556–62.

[132] Suzuki H, Araki M, Tatsugi K, Ichinohe K, Uehara T, Arano Y. Reduction of the renal radioactivity of 111In-DOTA-labeled antibody fragments with a linkage cleaved by the renal brush border membrane enzymes. J Med Chem. 2023;66(13):8600–13.

[133] Zhao L, Pang Y, Zhou Y, Chen J, Fu H, Guo W, et al. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade. Sig Trans & Targ Ther. 2024;9(1):142.

[134] Chen H, Zhao L, Fu K, Lin Q, Wen X, Jacobson O, et al. Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy. Theranostics. 2019;9(25):7948–60.

[135] Teng F, Kong L, Meng X, Yang J, Yu J. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. Cancer Lett. 2015;365(1):23–9.

RIGHTS & PERMISSIONS

2025 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.